Research progress of circulating and ocular biomarkers in screening and risk stratification and management of patients with early diabetic retinopathy

doi:10.3877/cma.j.issn.2095-2007.2023.05.010

Abstract

Abstract:

Diabetic retinopathy ( DR ) is the leading cause of blindness in working-age adults and one of the most common complications of diabetes. Timely detection and targeted intervention can effectively reduce the visual impairment caused by DR. However, the lack of typical symptoms in the early stage and the difficulty of large-scale long-term fundus screening often delayed the diagnosis and treatment of DR. The progress of circulating and ocular biomarkers in screening and risk stratification and management of patients with early diabetic retinopathy were reviewed in this paper, aiming to provide the reference for therapies and preventive interventions.

Key words: Biofluid, Biomarkers, Early stage of diabetic retinopathy, Screening, Management

Chanyan Huang, Yanchun Zhang, Jiamin Zheng, Xinchen Wang. Research progress of circulating and ocular biomarkers in screening and risk stratification and management of patients with early diabetic retinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(05): 306-310.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2023.05.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2023/V13/I05/306

References 56

[1]	Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta－analysis[J]. Ophthalmology, 2021, 128(11): 1580－1591.
[2]	Safi H, Safi S, Hafezi－Moghadam A, et al. Early detection of diabetic retinopathy[J]. Surv Ophthalmol, 2018, 63(5): 601－608.
[3]	Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges[J]. Lancet Diabetes Endo, 2020, 8(4): 337－347.
[4]	McAuley AK, Sanfilippo PG, Hewitt AW, et al. Vitreous biomarkers in diabetic retinopathy: a systematic review and meta－analysis[J]. J Diabetes Complicat, 2014, 28(3): 419－425.
[5]	Frudd K, Sivaprasad S, Raman R, et al. Diagnostic circulating biomarkers to detect vision——threatening diabetic retinopathy: Potential screening tool of the future？[J]. Acta Ophthalmologica, 2022, 100(3): 648－668.
[6]	Fong PY, Shih KC, Lam PY, et al. Role of tear film biomarkers in the diagnosis and management of dry eye disease[J]. Taiwan J Ophthalmol, 2019, 9(3): 150－159.
[7]	López－Contreras AK, Martínez－Ruiz MG, Olvera－Montaño C, et al. Importance of the use of oxidative stress biomarkers and inflammatory profile in aqueous and vitreous humor in diabetic retinopathy[J]. Antioxidants, 2020, 9(9): 891.
[8]	苗恒，赵明威. 眼内液标本采集和检测技术[J]. 中华眼科杂志，2020，56(4)：313－317.
[9]	Wu F, Phone A, Lamy R, et al. Correlation of aqueous, vitreous, and plasma cytokine levels in patients with proliferative diabetic retinopathy[J]. Invest Ophth Vis Sci, 2020, 61(2): 26－26.
[10]	Quek DQY, He F, Sultana R, et al. Novel serum and urinary metabolites associated with diabetic retinopathy in three Asian cohorts[J]. Metabolites, 2021, PMID: 34564429.
[11]	Abramoff MD, Fort PE, Han IC, et al. Approach for a clinically useful comprehensive classification of vascular and neural aspects of diabetic retinal disease[J]. Invest Ophth Vis Sci, 2018, 59(1): 519－527.
[12]	Xu C, Wu Y, Liu G, et al. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta－analysis[J]. Diagn Pathol, 2014, 9(1): 1－9.
[13]	Gong D, Fang L, Cai Y, et al. Development and evaluation of a risk prediction model for diabetes mellitus type 2 patients with vision－threatening diabetic retinopathy[J]. Front Endocrinol, 2023, PMID: 37693352.
[14]	Setareh J, Hoseinzade G, Khoundabi B, et al. Can the level of HbA1C predict diabetic retinopathy among type II diabetic patients？[J]. BMC ophthalmology, 2022, 22(1): 1－8.
[15]	Schreur V, van Asten F, Ng H, et al. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus[J]. Acta Ophthalmologica, 2018, 96(5): 459－464.
[16]	Matuszewski W, Stefanowicz－Rutkowska MM, Szychlińska M, et al. Differences in risk factors for diabetic retinopathy in type 1 and type 2 diabetes mellitus patients in north－east Poland[J]. Medicina, 2020, PMID: 32295214.
[17]	Choudhuri S, Dutta D, Sen A, et al. Role of N－epsilon－carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus[J]. Mol Vis, 2013, 19(1): 100－113.
[18]	Monnier VM, Sell DR, Gao X, et al. Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC[J]. BMJ Open Diabetes Research and Care, 2022, PMID: 35058313.
[19]	Yu L, Chen X, Qin G, et al. Tear film function in type 2 diabetic patients with retinopathy[J]. Ophthalmologica, 2008, 222(4): 284－291.
[20]	Mishra N, Saxena S, Shukla RK, et al. Association of serum Nε－Carboxy methyl lysine with severity of diabetic retinopathy[J]. J Diabetes Complicat, 2016, 30(3): 511－517.
[21]	Kerkeni M, Saïdi A, Bouzidi H, et al. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy[J]. Microvasc Res, 2012, 84(3)：378－383.
[22]	Ng ZX, Chua KH, Iqbal T, et al. Soluble receptor for advanced glycation end－product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy[J]. Int J Mol Sci, 2013, 14(4): 7480－7491.
[23]	Ahuja S, Saxena S, Akduman L, et al. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy[J]. Int J Retina Vitreous, 2019, 5: 1－6.
[24]	Jain A, Saxena S, Khanna VK, et al. Status of serum VEGF and ICAM－1 and its association with external limiting membrane and inner segment－outer segment junction disruption in type 2 diabetes mellitus[J]. Mol Vis, 2013, 19(8): 1760－1968.
[25]	Matsuyama K, Ogata N, Matsuoka M, et al. Relationship between pigment epithelium－derived factor (PEDF) and renal function in patients with diabetic retinopathy[J]. Mol Vis, 2008, 14(5)：992－996.
[26]	Zuo J, Lan Y, Hu H, et al. Metabolomics－based multidimensional network biomarkers for diabetic retinopathy identification in patients with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2021, PMID: 33593748.
[27]	Khaloo P, Qahremani R, Rabizadeh S, et al. Nitric oxide and TNF－alpha are correlates of diabetic retinopathy independent of hs－CRP and HbA1c[J]. Endocrine, 2020, 69(3): 536－541.
[28]	Curovic VR, Suvitaival T, Mattila I, et al. Circulating metabolites and lipids are associated to diabetic retinopathy in individuals with type 1 diabetes[J]. Diabetes, 2020, 69(10): 2217－2226.
[29]	Shen J, Zhang L, Wang Y, et al. Beneficial actions of essential fatty acids in streptozotocin－induced type 1 diabetes mellitus[J]. Frontiers in Nutrition, 2022, PMID: 35669071.
[30]	Zhu XR, Yang F, Lu J, et al. Plasma metabolomic profiling of proliferative diabetic retinopathy[J]. Nutr Metab, 2019, 16(1): 1－11.
[31]	Welsh P, Rankin N, Li Q, et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the advance trial[J]. Diabetologia, 2018, 61(5): 1581－1591.
[32]	Dong N, Shi H, Xu B, et al. Increased plasma S100A12 levels are associated with diabetic retinopathy and prognostic biomarkers of macrovascular events in type 2 diabetic patients[J]. Invest Ophth Vis Sci, 2015, 56(8): 4177－4185.
[33]	Hamano K, Nakadaira I, Suzuki J, et al. N－terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes[J]. Vasc Health Risk Manag, 2014，10(1): 585－589.
[34]	Hainsworth DP, Gangula A, Ghoshdastidar S, et al. Diabetic retinopathy screening using a gold nanoparticle－based paper strip assay for the at－home detection of the urinary biomarker 8－hydroxy－2′－deoxyguanosine[J]. Am Ophthalmol Mol, 2020, 213(5): 306－319.
[35]	Awata T, Yamashita H, Kurihara S, et al. A genome－wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non－coding RNA[J]. PLos One, 2014, 9(11): 1－9.
[36]	Burdon KP, Fogarty RD, Shen W, et al. Genome－wide association study for sight－threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene[J]. Diabetologia, 2015, 58(7): 2288－2297.
[37]	Pollack S, Igo RP, Jensen RA, et al. Multiethnic genome－wide association study of diabetic retinopathy using liability threshold modeling of duration of diabetes and glycemic control[J]. Diabetes, 2019, 68(2): 441－456.
[38]	Yu X, Rong S. Genome－wide associations and confirmatory meta－analyses in diabetic retinopathy[J]. Genes, 2023, 14(3): 653－665.
[39]	Jian Q, Wu Y, Zhang F. Metabolomics in diabetic retinopathy: from potential biomarkers to molecular basis of oxidative stress[J]. Cells, 2022, 11(19): 3005－3024.
[40]	Patel C, Rojas M, Narayanan SP, et al. Arginase as a mediator of diabetic retinopathy[J]. Front Immunol, 2013, 4(1): 173－184.
[41]	Sharma R, Gupta A, Thungapathra M, et al. Telomere mean length in patients with diabetic retinopathy[J]. Sci Rep, 2015, 5(1): 1－6.
[42]	Mishra M, Lillvis J, Seyoum B, et al. Peripheral blood mitochondrial DNA damage as a potential noninvasive biomarker of diabetic retinopathy[J].Invest Ophth Vis Sci, 2016, 57(10): 4035－4044.
[43]	Xiong F, Du X, Hu J, et al. Altered retinal microRNA expression profiles in early diabetic retinopathy: an in silico analysis[J]. Curr Eye Res, 2014, 39(7): 720－729.
[44]	Zampetaki A, Willeit P, Burr S, et al. Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes[J]. Diabetes, 2016, 65(1): 216－227.
[45]	Kim K, Kim SJ, Han D, et al. Verification of multimarkers for detection of early stage diabetic retinopathy using multiple reaction monitoring[J]. J Proteome Res, 2013, 12(3): 1078－1089.
[46]	Liu YP, Hu SW, Wu ZF, et al. Proteomic analysis of human serum from diabetic retinopathy[J]. Int J Opthalmol－Chi, 2011, 4(6): 616－622.
[47]	Torok Z, Peto T, Csosz E, et al. Tear fluid proteomics multimarkers for diabetic retinopathy screening[J]. Bmc Ophthalmol, 2013, 13(1): 1－8.
[48]	Kim HJ, Kim PK, Yoo HS, et al. Comparison of tear proteins between healthy and early diabetic retinopathy patients[J]. Clin Biochem, 2012, 45(1－2): 60－67.
[49]	Yamada M, Mochizuki H, Kawai M, et al. Decreased tear lipocalinconcentration in patients with meibomian gland dysfunction[J]. Br J Ophthalmol, 2005, 89: 803－805.
[50]	Jin H, Zhu B, Liu X, et al. Metabolic characterization of diabetic retinopathy: An 1H－NMR－based metabolomic approach using human aqueous humor[J]. J Pharmaceut Biomed, 2019, 174(11): 414－421.
[51]	Tamhane M, Cabrera－Ghayouri S, Abelian G, et al. Review of biomarkers in ocular matrices: challenges and opportunities[J]. Pharm Res, 2019, 36(3): 40－75.
[52]	Xuan Q, Ouyang Y, Wang Y, et al. Multiplatform metabolomics reveals novel serum metabolite biomarkers in diabetic retinopathy subjects[J].Adv Sci, 2020, 7(22): 1－10.
[53]	Rhee SY, Jung ES, Park HM, et al. Plasma glutamine and glutamic acid are potential biomarkers for predicting diabetic retinopathy[J]. Metabolomics, 2018, 14(2): 1－10.
[54]	Lin HT, Cheng ML, Lo CJ, et al. 1H nuclear magnetic resonance (NMR)－based cerebrospinal fluid and plasma metabolomic analysis in type 2 diabetic patients and risk prediction for diabetic microangiopathy[J]. J Clin Med, 2019, 8(6): 874－896.
[55]	Haines NR, Manoharan N, Olson JL, et al. Metabolomics analysis of human vitreous in diabetic retinopathy and rhegmatogenous retinal detachment[J]. J Proteome Res, 2018, 17(7): 2421－2427.
[56]	Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult－onset diabetes and their association with outcomes: a data－driven cluster analysis of six variables[J]. Lancet Diabetes Endo, 2018, 6(5): 361－369.

Please choose a citation manager

Content to export